AI technology company launches with Novartis and Sarepta deals
Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.
Dyno Therapeutics emerges from stealth with two strategic collaborations with Novartis and Sarepta to develop improved gene therapies with Adeno-Associated Virus (AAV vectors) based on artificial intelligence (AI) technology.
Novartis collaboration
The biotechnology company's deal with Novartis will focus on developing improved AAV vectors for research, development, and commercialization of gene therapies for ocular diseases.The partnership will allow the parties to utilize Dyno’s CapsidMap AI platform along with Novartis expertise in ophthalmology and gene therapy development and global commercialization to deliver innovative gene therapies to patients with serious diseases of the eye.
According to Eric D. Kelsic, CEO and Co‑founder of Dyno Therapeutics, many eye diseases are particularly suitable for gene therapy treatment, and new and improved AAV vectors could open up more opportunities.
Dyno will use AI technology and its suite of machine learning and experimental tools for the design and discovery of novel AAV capsids, the cell-targeting protein shell of viral vectors, with improved functional properties for gene therapy.
Novartis will conduct preclinical, clinical, and commercialization activities for the gene therapy product candidates created with the novel AAV capsids.
Dyno will receive upfront consideration plus committed research funding and license fees. In addition, Dyno will be eligible to receive clinical, regulatory and sales milestone payments, as well as royalties on worldwide net sales of any commercial products developed through the partnership.
In a separate deal, Dyno and Sarepta Therapeutics will work together to develop next-generation AAV vectors for muscle diseases, also using Dyno’s CapsidMap platform.
AI and machine learning technologies have the potential to deliver enhanced vectors for gene therapies. Dyno’s proprietary CapsidMap platform offers new ways to identify novel capsids that could offer improved muscle targeting and immune-evading properties, in addition to advantages in packaging and manufacturing.
Under the terms of this agreement, Dyno will be responsible for the design and discovery of novel AAV capsids with improved functional properties for gene therapy whereas Sarepta will be responsible for conducting preclinical, clinical and commercialization activities for gene therapy product candidates using the novel capsids.
If successful, Dyno could receive more than $40 million in upfront, option and license payments during the research phase of the collaboration.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance